** U.S.-listed shares of cancer drug developer BeiGene 688235.SS, ONC.O fall 3.2% to $266.03
** Co says it is discontinuing development of its experimental lung cancer drug, ociperlimab, in a late-stage trial
** Independent data monitoring committee recommended terminating the trial
** Study unlikely to meet the main goal of improving overall survival, co says
** As of last close, ONC up ~49% YTD vs. 2.4% decline in the Nasdaq biotechnology index .NBI
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。